Navigation Links
CSL Behring Receives EU Orphan Drug Designations for rVIIa-FP for Hemophilia A and B Treatment
Date:5/31/2011

KING OF PRUSSIA, Pa., May 31, 2011 /PRNewswire/ -- CSL Behring announced today that it has been granted Orphan Drug Designations (ODD) by the European Commission for the development of its recombinant fusion protein linking coagulation factor VIIa with albumin (rVIIa-FP), a novel therapy to treat hemophilia A and hemophilia B patients with inhibitors. The designations would entitle CSL Behring to exclusively market recombinant factor VIIa fused with albumin in Europe for a period of 10 years if the product at the stage of license application fulfils the orphan drug requirements. Based on the submission of data from the company's Pediatric Investigation Plan, once available, the 10-year market exclusivity may be extended to 12 years.

Under these designations European Medicines Agency (EMA) will also provide CSL Behring with development assistance and with reductions in certain regulatory fees.

"CSL Behring welcomes Orphan Drug Designation for rVIIa-FP as support of our ongoing commitment to developing, manufacturing and marketing products for the treatment of rare and serious diseases, such as hemophilia with inhibitors," said Val Romberg, Senior Vice President, Global Research & Development. "We will continue to work closely with the EMA to make this important therapy available to patients as soon as possible."

An orphan drug designation application has not yet been submitted in the United States.

By providing incentives to the pharmaceutical industry, the EU legislative framework for orphan medicines encourages the development of products intended to diagnose, prevent and treat life-threatening or chronically-debilitating conditions that impact up to 5 in 10,000 people in the European Union. The initiative helps improve access to quality medical care for patients who have rare diseases for which there are few, if any, approved treatments.

About Hemophilia

Hemoph
'/>"/>

SOURCE CSL Behring
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. National Organization for Rare Disorders Presents CSL Behring With 2011 Corporate Award
2. CSL Behring Marks World Hemophilia Day with Coagulation Factor Donation to World Federation of Hemophilia
3. CSL Behring Medical Product Donation Helps Meet Critical Need for Ongoing Cholera Relief Effort in Haiti
4. CSL Behring Announces Completion of National Marketing Authorizations of Berinert® After MRP in 23 European Countries
5. CSL Behring Announces FDA Approval of Berinert(R), First and Only Therapy Approved for the Treatment of Acute Abdominal and Facial Attacks of Hereditary Angioedema in U.S.
6. CSL Behring Receives Orphan-Drug Exclusivity for RiaSTAP(TM), First and Only Approved Treatment of Acute Bleeding Episodes in Patients with Congenital Fibrinogen Deficiency
7. Over $10 Million of CSL Behrings Privigen Was Sold in the U.S. During the Third Quarter of 2008
8. CSL Behring Submits BLA Requesting Approval of C1-Esterase Inhibitor for the Treatment of Hereditary Angioedema
9. CSL Behring Study in Animal Models Shows Feasibility of Developing a Half-Life Extended Recombinant FVIIa that Retains Biologic Activity
10. CSL Behring Reaches Primary Endpoint in Clinical Study of C1-INH for Treatment of Hereditary Angioedema
11. Bacterin International Receives $1 million Initial Investment of $31 Million Purchase Agreement with Lincoln Park Capital Fund, LLC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... 2014 Kewaunee Scientific Corporation (Nasdaq: ... its quarterly cash dividend by 9% to twelve cents ... beginning with the dividend payable on September 22, 2014 ... on September 8, 2014. About Kewaunee ... Scientific Corporation is a recognized global leader in the ...
(Date:8/27/2014)... NINGBO, China , Aug. 27, 2014 /PRNewswire/ ... Co., Ltd, ("Menovo") today announced they had entered into ... primarily targeting the United States ... Menovo will jointly develop products for Amerigen to commercialize ... will be responsible for manufacturing API and finished product ...
(Date:8/27/2014)... 27, 2014 Ambit Biosciences (Nasdaq: AMBI ), ... targeting unmet needs in oncology, autoimmune and inflammatory disease, today ... Conference to be held at The New York Palace Hotel ... 3-4, 2014. Alan Fuhrman , Ambit,s CFO, ... drug candidate, quizartinib, at 1:10 p.m. ET on Wednesday, September ...
Breaking Medicine Technology:Amerigen Pharmaceuticals Limited and the Ningbo Menovo Pharmaceutical Co., Ltd, today announced they had entered into a collaboration agreement regarding the development of generic pharmaceuticals, primarily targeting the United States market 2Ambit Announces Participation At Baird 2014 Health Care Conference 2
(Date:8/28/2014)... New York (PRWEB) August 28, 2014 An ... back and neck issues, Cloud 9 Spine offers their resources ... spine problems can quickly become a brick wall of discouragement ... for a professional opinion, Cloud 9 Spine offers ... proprietary technology merged with human interaction that sets Cloud 9 ...
(Date:8/28/2014)... Alpine, NJ resident Othon Mourkakos is proud to ... Tiaras, to benefit the Immune Deficiency Foundation (IDF) Walk ... in Foley Square, New York. IDF is the ... (PI) are a group of more than 200 rare, ... immune system is missing or functions improperly. In ...
(Date:8/28/2014)... The revenue cycle process touches on ... time a patient books an appointment with a physician’s ... payments for services rendered to the healthcare provider. ... has the RCM process down to a science. Over ... common place in nearly every healthcare facility around the ...
(Date:8/27/2014)... Asheville, NC (PRWEB) August 28, 2014 ... for companies to acquire as part of a ... business. Aeroflow is positioned for taking ownership of ... foundation to increase economies of scale. , Last ... an agreement with Hometown Respiratory to increase service ...
(Date:8/27/2014)... Spine Guide has built a reputation for itself ... health. Now, the e-health site will offer new surgical ... pain symptoms. Spine Guide specializes in three types of ... surgery. , Some of the most common back pain ... radiating down the leg, inability to stand up straight, ...
Breaking Medicine News(10 mins):Health News:Making Waves on the East Coast, Cloud 9 Spine is Helping Patients Find Appointments With Local Spine Doctors 2Health News:Tips on Automating the Revenue Cycle Process with Medical Billing 2Health News:Tips on Automating the Revenue Cycle Process with Medical Billing 3Health News:Aeroflow Healthcare Seeks Strategic Acquisition Opportunities 2Health News:Spine Guide Offering New Overview of Surgical Options For Back Pain 2
... Switzerland and Brussels, Belgium, 9 April 2008: The European ... European CanCer Organisation have united forces to host a ... best and most updated scientific data for everyone working ... providing all cancer patients with equal access to high-quality ...
... 2008 Ever wonder if,your doctor personally follows the ... to the recent "Life ... supplemented" Healthcare,Professionals (HCP) Impact ... behaviors, with three of the top shared healthy behaviors,being: ... regularly (73,percent) and taking vitamins and other supplements (72 ...
... Research, Programs for #1 Cause of,Fatal and Nonfatal Injuries ... A broad-based,coalition of nonprofit organizations dedicated to improving the ... of S. 845, the Safety,of Seniors (SOS) Act, clearing ... point: each year, one in three older Americans (65 ...
... counterintuitive to exercise when suffering with joint pain, but ... most people suffering from arthritis. A recent study ... regular exercise, specifically the Arthritis Foundation Exercise Program, is ... pain. This is good news for the aging ...
... April 8, 2008 The Procter &,Gamble Company (NYSE: ... in the quarterly dividend from thirty-five cents ($0.35) to forty,cents ... Series A and Series,B ESOP Convertible Class A Preferred Stock ... shareholders of record at the close of business on,April 18, ...
... Chinese studies show cancer treatment extended survival time in ... combination of the active ingredients in reishi mushrooms and ... survival time of mice with sarcomas, two Chinese studies ... fat, muscle, blood vessels, or other connective or supportive ...
Cached Medicine News:Health News:European Society for Medical Oncology and European CanCer Organization join forces 2Health News:Doctors' and Nurses' Wellness Checklist: Healthy Diet, Exercise, Dietary Supplements 2Health News:Doctors' and Nurses' Wellness Checklist: Healthy Diet, Exercise, Dietary Supplements 3Health News:Elder Falls Bill Passes Congress, Heads to President 2Health News:Elder Falls Bill Passes Congress, Heads to President 3Health News:Physical activity is natural pain reliever for arthritis 2Health News:Green Tea, Mushroom Extract Combo Slows Sarcomas 2
The High Pure Viral RNA Kit is intended for general laboratory use and is designed to purify viral RNA from serum or plasma. Viral RNA is used for RT-PCR analysis directly after elution in nuclease-f...
... This revolutionary product will provide you ... type of electroretinogram, visual evoked potential, ... ganzfeld will allow you to perform ... on-off, double flash, photopic negative response, ...
The PersonalLAB junior is an automated microplate analyzer capable of fully automating immunoenzymatic techniques using a microplate format, per the reagent manufacturer's instruction for use and spe...
... is designed for high throughput microplate processing. ... S60 Stacker that handles up to 60 ... base model is equipped with a dual ... units may be interfaced to increase flexibility ...
Medicine Products: